Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase‐3β

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Annals of Neurology

• Publication date

  2008-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ana.21325PMID 18318434
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Gne knockout mouse expressing human V572L mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy.

  2007cited by this paper
• A Gne knockout mouse expressing human GNE D176V mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy.

  2007cited by this paper
• Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice.

  2007cited by this paper
• Increased level of active GSK‐3β in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration

  2007cited by this paper
• Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.

  2007cited by this paper
• Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice.

  2006cited by this paper
• Newer therapeutic approaches: inflammatory muscle disorders.

  2006cited by this paper
• Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies

  2006cited by this paper
• Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model.

  2006cited by this paper
• Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease

  2005cited by this paper
• Glycogen Synthase Kinase-3 Mediates Endothelial Cell Activation by Tumor Necrosis Factor-α

  2005cited by this paper
• Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders.

  2005cited by this paper
• Lithium Chloride Increases the Production of Amyloid-β Peptide Independently from Its Inhibition of Glycogen Synthase Kinase 3*

  2005cited by this paper
• Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies

  2005cited by this paper
• Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.

  2005cited by this paper
• Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing.

  2004cited by this paper
• Dermatomyositis and polymyositis

  2003cited by this paper
• Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice.

  2003cited by this paper
• Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies

  2003cited by this paper
• Expression of IFN-gamma-inducible chemokines in inclusion body myositis.

  2003cited by this paper
• Expression of IFN-γ-inducible chemokines in inclusion body myositis

  2003cited by this paper
• Inclusion body myositis.

  2002cited by this paper
• [Dermatomyositis and polymyositis].

  2002cited by this paper
• Inclusion body myositis-like phenotype induced by transgenic overexpression of βAPP in skeletal muscle

  2002cited by this paper
• Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP

  2001cited by this paper
• Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils

  2001cited by this paper
• Beta-amyloid peptide expression is sufficient for myotube death: implications for human inclusion body myopathy.

  2001cited by this paper
• Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies.

  2000cited by this paper
• Cyclin-dependent kinase 5 colocalizes with phosphorylated tau in human inclusion-body myositis paired-helical filaments and may play a role in tau phosphorylation.

  2000cited by this paper
• Novel Immunolocalization of α‐Synuclein in Human Muscle of Inclusion‐Body Myositis, Regenerating and Necrotic Muscle Fibers, and at Neuromuscular Junctions

  2000cited by this paper
• Aberrant expression of cyclin-dependent kinase 5 in inclusion body myositis

  1999influential reference
• Transgenic Mice Over-Expressing the C-99 Fragment of βPP with an α-Secretase Site Mutation Develop a Myopathy Similar to Human Inclusion Body Myositis

  1998cited by this paper
• Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis.

  1998cited by this paper
• Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy.

  1998cited by this paper
• Difference in Expression of Phosphorylated Tau Epitopes between Sporadic Inclusion‐body Myositis and Hereditary Inclusion‐body Myopathies

  1996cited by this paper
• Localization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies

  1996cited by this paper
• Sporadic inclusion body myositis: Counts of different types of abnormal fibers

  1996cited by this paper
• Apolipoprotein E immunoreactive deposits in inclusion-body muscle diseases.

  1994cited by this paper
• Ubiquitin expression in inclusion body myositis. An immunohistochemical study.

  1993cited by this paper
• Inclusion body myositis : clinical and histopathological features of 36 patients

  1993cited by this paper
• beta-Amyloid precursor epitopes in muscle fibers of inclusion body myositis.

  1993cited by this paper
• β‐Amyloid precursor epitopes in muscle fibers of inclusion body myositis

  1993cited by this paper
• Clinical, immunopathologic, and therapeutic considerations of inflammatory myopathies.

  1992cited by this paper
• Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies.

  1989cited by this paper
• Transgenic expression of (cid:1) -APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology

  year unknowncited by this paper

• Rhynchophylline alleviates cognitive deficits in multiple transgenic mouse models of Alzheimer’s disease via modulating neuropathology and gut microbiota

  2025cites this paper
• Transgenic sensors reveal compartment-specific effects of aggregation-prone proteins on subcellular proteostasis during aging

  2024cites this paper
• Lactocaseibacillus-deglycosylated isoflavones prevent Aβ 40-induced Alzheimer’s disease in a rat model

  2024cites this paper
• Sporadic Inclusion Body Myositis at the Crossroads between Muscle Degeneration, Inflammation, and Aging

  2024cites this paper
• Autoimmune inflammatory myopathies.

  2023cites this paper
• Advances in the Therapeutic Potential of Inhibitors Targeting Glycogen Synthase Kinase 3 in Inflammatory Diseases.

  2023cites this paper
• Inclusion body myositis: evolving concepts

  2022cites this paper
• Lithium can mildly increase health during ageing but not lifespan in mice

  2021influential citation
• Revisiting the Role of GSK3, A Modulator of Innate Immunity, in Idiopathic Inclusion Body Myositis

  2021cites this paper
• Update on Myositis Therapy: from Today's Standards to Tomorrow's Possibilities.

  2021cites this paper
• Inflammatory myopathies: shedding light on promising agents and combination therapies in clinical trials

  2021cites this paper
• Normas

  2020cites this paper
• New insights into the treatment of myositis

  2020cites this paper
• Astrocytes and Inflammatory Processes in Alzheimer’s Disease

  2020cites this paper
• Cellular Stress in the Pathogenesis of Muscular Disorders—From Cause to Consequence

  2020cites this paper
• Berberine: A plant derived alkaloid with therapeutic potential to combat Alzheimer's disease.

  2019cites this paper
• Resistance Exercise Improves Mitochondrial Quality Control in a Rat Model of Sporadic Inclusion Body Myositis

  2019cites this paper
• Lithium chloride corrects weakness and myopathology in a preclinical model of LGMD1D

  2019cites this paper
• Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease

  2018cites this paper
• Dysregulated innate immune function in the aetiopathogenesis of idiopathic inflammatory myopathies.

  2017influential citation
• Immune and myodegenerative pathomechanisms in inclusion body myositis

  2017cites this paper
• Sporadic Inclusion Body Myositis : A myodegenerative disease or an inflammatory myopathy

  2017cites this paper
• Advances in inclusion body myositis: genetics, pathogenesis and clinical aspects

  2017influential citation
• Genetic Investigations of Sporadic Inclusion Body Myositis and Myopathies with Structural Abnormalities and Protein Aggregates in Muscle

  2016cites this paper
• Role of berberine in Alzheimer’s disease

  2016cites this paper
• Sporadic inclusion-body myositis: A degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy.

  2015influential citation
• Compartment-dependent mitochondrial alterations in experimental ALS, the effects of mitophagy and mitochondriogenesis

  2015cites this paper
• Emerging therapeutic options for sporadic inclusion body myositis

  2015cites this paper
• Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken

  2015cites this paper
• Lithium Modulates Autophagy in Esophageal and Colorectal Cancer Cells and Enhances the Efficacy of Therapeutic Agents In Vitro and In Vivo

  2015cites this paper
• Formaldehyde as a trigger for protein aggregation and potential target for mitigation of age-related, progressive cognitive impairment.

  2015cites this paper
• Neuromuscular Pathology Case.

  2015cites this paper
• emerging therapeutic options for sporadic inclusion body myositis

  2015cites this paper
• Toward Computational Cumulative Biology by Combining Models of Biological Datasets

  2014cites this paper
• 2 Sporadic inclusion-body myositis: A degenerative muscle disease 3 associated with aging, impaired muscle protein homeostasis and

  2014cites this paper
• Restoration of Lipoxin A4 Signaling Reduces Alzheimer's Disease-Like Pathology in the 3xTg-AD Mouse Model

  2014cites this paper
• Leucine‐rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase‐3β

  2014cites this paper
• Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis.

  2014cites this paper
• Treatment strategies for inclusion body myositis

  2014cites this paper
• Update on Treatment of Inclusion Body Myositis

  2013cites this paper
• International Workshop : Inclusion Body Myositis , 2 – 4 December 2011 , Naarden , The Netherlands

  2013cites this paper
• Update in inclusion body myositis

  2013cites this paper
• Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives

  2013cites this paper
• Activation of the γ-secretase complex and presence of γ-secretase-activating protein may contribute to Aβ42 production in sporadic inclusion-body myositis muscle fibers.

  2012cites this paper
• Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β-induced accumulation of β-amyloid and cell death.

  2012cites this paper
• Muscle Aging, Inclusion-Body Myositis and Myopathies: Askanas/Muscle Aging, Inclusion-Body Myositis and Myopathies

  2012cites this paper
• Pathogenic Considerations in Sporadic Inclusion-Body Myositis, a Degenerative Muscle Disease Associated With Aging and Abnormalities of Myoproteostasis

  2012cites this paper
• Métabolisme et pathologie Tau dans la maladie d'Alzheimer : une relation réciproque ? : Metabolism and Tau pathology in Alzheime's disease : a reciprocal relationship ?

  2012cites this paper
• Inflammatory and Autoimmune Features of Inclusion‐Body Myositis

  2011cites this paper
• [Standard treatment for myositis and muscular dystrophies].

  2011cites this paper
• Review: An update on inflammatory and autoimmune myopathies

  2011cites this paper
• Blocking IL-1 Signaling Rescues Cognition, Attenuates Tau Pathology, and Restores Neuronal β-Catenin Pathway Function in an Alzheimer’s Disease Model

  2011cites this paper
• Pathophysiology of inflammatory and autoimmune myopathies.

  2011cites this paper
• Novel demonstration of conformationally modified tau in sporadic inclusion-body myositis muscle fibers.

  2011cites this paper
• Lipopolysaccharide‐induced tau phosphorylation and kinase activity – modulation, but not mediation, by corticotropin‐releasing factor receptors

  2011cites this paper
• Inflammation induced by infection potentiates tau pathological features in transgenic mice.

  2011cites this paper
• Inclusion body myositis: diagnosis, pathogenesis, and treatment options.

  2011cites this paper
• Therapiestandard bei Myositiden und Muskeldystrophien

  2011cites this paper
• Expression of human amyloid precursor protein in the skeletal muscles of Drosophila results in age- and activity-dependent muscle weakness

  2011cites this paper
• Pathogenesis of Sporadic Inclusion‐Body Myositis: Role of Aging and Muscle‐Fiber Degeneration, and Accumulation of the Same Proteins as in Alzheimer and Parkinson Brains

  2011cites this paper
• Therapiestandard bei Myositiden und Muskeldystrophien

  2011cites this paper
• Inclusion Body Myositis

  2011cites this paper
• Tau Phosphorylation in Myotilinopathies and Desminopathies

  2010cites this paper
• Inflammatory muscle diseases: a critical review on pathogenesis and therapies.

  2010cites this paper
• Intracellular pathways underlying the effects of lithium

  2010cites this paper
• Inclusion-body myositis in the elderly: an update

  2010cites this paper
• Gene therapy for myositis

  2010cites this paper
• Patologia molecular de les miopaties miofibril·lars

  2010cites this paper
• Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies.

  2010cites this paper
• Theories of the Pathogenesis of Inclusion Body Myositis

  2010cites this paper
• Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers.

  2010cites this paper
• Pathomechanisms of inflammatory myopathies : recent advances and implications for diagnosis and therapies

  2010cites this paper
• Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis

  2009cites this paper
• Role of cytokines and chemokines in idiopathic inflammatory myopathies

  2009cites this paper
• Pathogenese der Einschlusskörperchenmyositis: Stellenwert der Entzündung und Bedeutung für Therapiestrategien

  2009cites this paper
• Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors.

  2009cites this paper
• Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of αB-crystallin is associated with amyloid precursor protein and accumulation of β-amyloid

  2009cites this paper
• Nature of “Tau” immunoreactivity in normal myonuclei and inclusion body myositis

  2009cites this paper
• Sporadic inclusion body myositis: Pathogenic considerations

  2009cites this paper
• Autophagy, lithium, and amyotrophic lateral sclerosis

  2009cites this paper
• Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis

  2009cites this paper
• Inclusion body myositis: Review of recent literature

  2009influential citation
• Sporadic inclusion body myositis: an unsolved mystery.

  2009cites this paper
• Immunization with Amyloid-β Attenuates Inclusion Body Myositis-Like Myopathology and Motor Impairment in a Transgenic Mouse Model

  2009cites this paper
• Inclusion body myositis: old and new concepts

  2009cites this paper
• Inflammatory myopathies: disease mechanisms

  2009cites this paper
• Inclusion Body Myositis: A View from the Caenorhabditis elegans Muscle

  2008cites this paper
• Animal models in myositis

  2008cites this paper
• Inclusion body myositis: new insights into pathogenesis

  2008cites this paper
• Current world literature.

  2008cites this paper
• Neuromuscular pathology case.

  2008cites this paper
• Neuromuscular pathology case.

  2008cites this paper
• Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer’s and Parkinson’s disease brains

  2008cites this paper